SciTransfer
Organization

VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL

Sweden's national research funding agency, coordinating transnational ERA-NET programmes with a leadership role in antimicrobial resistance research.

National research funding agencyhealthSE
H2020 projects
23
As coordinator
3
Total EC funding
€22.8M
Unique partners
503
What they do

Their core work

The Swedish Research Council (Vetenskapsrådet) is Sweden's largest governmental funding agency for basic research across all scientific disciplines. In H2020, it primarily acts as a national funding body coordinating transnational research programs — pooling national budgets with other European funders to launch joint calls in areas like antimicrobial resistance, neurodegenerative diseases, and quantum technologies. It does not conduct research itself but shapes research agendas, manages ERA-NET co-funded programs, and ensures Swedish alignment with European research priorities. Its role is strategic: deciding what gets funded, how national programs connect to EU initiatives, and driving policy on open science and FAIR data.

Core expertise

What they specialise in

Antimicrobial resistance (AMR) research coordinationprimary
3 projects

Coordinated all three AMR-related projects: JPI-EC-AMR, EXEDRA, and JPIAMR-ACTION, spanning 2015-2026 — the only topic where VR leads rather than follows.

ERA-NET co-funded programme managementprimary
16 projects

16 of 23 projects use the ERA-NET-Cofund scheme, making transnational call management and multi-country funding alignment their core operational competence.

Neurodegenerative disease research fundingsecondary
3 projects

Participated in JPco-fuND, JPsustaiND, and JPCOFUND2 — all supporting the Joint Programming Initiative on Neurodegenerative Diseases (JPND).

Quantum technologies funding coordinationsecondary
2 projects

Participated in both QuantERA (2016) and QuantERA II (2021), co-funding transnational research in quantum computing, sensing, and communication.

1 project

Participated in GENDER NET Plus, integrating sex and gender analysis into research funding decisions — reflecting VR's policy mandate beyond pure science funding.

Evolution & trajectory

How they've shifted over time

Early focus
Disease-specific joint programming
Recent focus
Open science and data infrastructure

In 2014-2018, VR focused heavily on disease-specific joint programming (neurodegenerative diseases, antimicrobial resistance) and humanities research coordination, reflecting traditional research council priorities. From 2019 onward, their portfolio shifted markedly toward research infrastructure and policy: open science, FAIR data, EOSC integration, and continued but broadened AMR work focused on transmission interventions. The evolution signals a move from topic-specific funding coordination toward shaping the structural conditions of European research itself.

VR is increasingly positioning itself at the intersection of research policy and digital infrastructure, making it a strong partner for projects requiring national funding alignment with EOSC and FAIR data mandates.

Collaboration profile

How they like to work

Role: active_partnerReach: Global47 countries collaborated

VR overwhelmingly participates as a partner (19 of 23 projects) but takes the coordinator role specifically in AMR — their flagship topic. Their 503 unique partners across 47 countries reveal a massive, shallow network typical of a national funding agency that joins broad ERA-NET consortia rather than deep bilateral collaborations. Working with VR means gaining access to Swedish national funding streams and alignment with Swedish research priorities, but they are a policy and funding partner, not a research execution partner.

With 503 unique consortium partners across 47 countries, VR has one of the broadest networks in H2020 — a direct consequence of participating in large ERA-NET consortia that typically include 20-40 national funding agencies each. Their network is pan-European by design, with no strong geographic bias beyond the expected Nordic connections.

Why partner with them

What sets them apart

VR is not a research performer — it is a research funder and policy shaper. This makes it uniquely valuable for projects that need national funding alignment, co-funded call management, or a credible government partner to anchor a consortium. For AMR specifically, VR has built a decade-long track record as coordinator of the Joint Programming Initiative, making it the natural lead for any new European AMR funding initiative.

Notable projects

Highlights from their portfolio

  • EUROfusion
    By far the largest single grant at EUR 12.2M — Sweden's participation in the roadmap to fusion energy, dwarfing all other VR project budgets combined.
  • JPIAMR-ACTION
    VR's most recent coordinator role (2021-2026), representing the culmination of a decade-long AMR coordination effort spanning three successive projects.
  • EOSC-Nordic
    Marks VR's entry into research data infrastructure — connecting Nordic countries to the European Open Science Cloud, signaling their strategic shift toward open science.
Cross-sector capabilities
Research policy and funding coordinationOpen science and FAIR data governanceQuantum technologies programme managementEnvironmental and climate research funding
Analysis note: VR's profile is clear and data-rich, but their role as a funding agency rather than research performer means their 'expertise' is in programme management and policy, not technical research. The EUR 12.2M EUROfusion grant skews the funding average significantly — most of their other contributions are in the EUR 200K-500K range typical for ERA-NET partners. One project (EOSC Future) lists them as third party, suggesting indirect involvement.